BR112018069174A2 - tratamento de prurido urêmico - Google Patents
tratamento de prurido urêmicoInfo
- Publication number
- BR112018069174A2 BR112018069174A2 BR112018069174A BR112018069174A BR112018069174A2 BR 112018069174 A2 BR112018069174 A2 BR 112018069174A2 BR 112018069174 A BR112018069174 A BR 112018069174A BR 112018069174 A BR112018069174 A BR 112018069174A BR 112018069174 A2 BR112018069174 A2 BR 112018069174A2
- Authority
- BR
- Brazil
- Prior art keywords
- treatment
- uremic
- itching
- uremic itching
- patient
- Prior art date
Links
- 208000003251 Pruritus Diseases 0.000 title 1
- 230000007803 itching Effects 0.000 title 1
- 206010060875 Uraemic pruritus Diseases 0.000 abstract 1
- 230000001139 anti-pruritic effect Effects 0.000 abstract 1
- 239000003908 antipruritic agent Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Emergency Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Inorganic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662311134P | 2016-03-21 | 2016-03-21 | |
| US201662412584P | 2016-10-25 | 2016-10-25 | |
| PCT/US2017/023398 WO2017165409A1 (en) | 2016-03-21 | 2017-03-21 | Treatment of uremic pruritus |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112018069174A2 true BR112018069174A2 (pt) | 2019-01-29 |
Family
ID=59899743
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112018069174A BR112018069174A2 (pt) | 2016-03-21 | 2017-03-21 | tratamento de prurido urêmico |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US20180008592A1 (enExample) |
| EP (1) | EP3432871B1 (enExample) |
| JP (2) | JP2019509309A (enExample) |
| KR (1) | KR20180120756A (enExample) |
| CN (1) | CN109310656A (enExample) |
| AU (1) | AU2017238051B9 (enExample) |
| BR (1) | BR112018069174A2 (enExample) |
| CA (1) | CA3017374A1 (enExample) |
| ES (1) | ES2970294T3 (enExample) |
| MX (1) | MX382608B (enExample) |
| WO (1) | WO2017165409A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019301134A1 (en) * | 2018-07-11 | 2021-01-21 | Trevi Therapeutics, Inc. | Treatment of the pruritic symptoms of liver disease |
| CN118512451A (zh) | 2018-07-23 | 2024-08-20 | 特雷维治疗股份有限公司 | 慢性咳嗽、呼吸急促和呼吸困难的治疗 |
| IL294601A (en) | 2020-01-10 | 2022-09-01 | Trevi Therapeutics Inc | Methods of administration of nalbuphine |
| WO2021222886A1 (en) * | 2020-05-01 | 2021-11-04 | Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College | Compositions and methods to treat polycystic kidney disease |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1535687A (zh) * | 1996-11-25 | 2004-10-13 | ������������ʽ���� | 止痒药物 |
| WO2009047562A1 (en) * | 2007-10-08 | 2009-04-16 | Serentis Limited | Methods and compositions for the treatment of pruritus |
| US8686040B2 (en) * | 2008-03-31 | 2014-04-01 | Rdd Pharma Ltd. | Method for treating anal pruritis and other perianal disorders |
| US8637538B1 (en) * | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
| JP2016506398A (ja) * | 2012-12-14 | 2016-03-03 | トレビ セラピューティクス インコーポレイテッド | そう痒の処置法 |
| US8987289B2 (en) * | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
| WO2015192071A1 (en) * | 2014-06-13 | 2015-12-17 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
-
2017
- 2017-03-21 CA CA3017374A patent/CA3017374A1/en active Pending
- 2017-03-21 CN CN201780025588.8A patent/CN109310656A/zh active Pending
- 2017-03-21 WO PCT/US2017/023398 patent/WO2017165409A1/en not_active Ceased
- 2017-03-21 BR BR112018069174A patent/BR112018069174A2/pt not_active IP Right Cessation
- 2017-03-21 ES ES17770981T patent/ES2970294T3/es active Active
- 2017-03-21 US US15/465,158 patent/US20180008592A1/en not_active Abandoned
- 2017-03-21 MX MX2018011379A patent/MX382608B/es unknown
- 2017-03-21 EP EP17770981.3A patent/EP3432871B1/en active Active
- 2017-03-21 KR KR1020187029246A patent/KR20180120756A/ko not_active Ceased
- 2017-03-21 JP JP2018549563A patent/JP2019509309A/ja active Pending
- 2017-03-21 AU AU2017238051A patent/AU2017238051B9/en active Active
-
2022
- 2022-03-17 JP JP2022042056A patent/JP2022081640A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| MX2018011379A (es) | 2019-06-13 |
| US20180008592A1 (en) | 2018-01-11 |
| EP3432871A1 (en) | 2019-01-30 |
| EP3432871B1 (en) | 2023-11-15 |
| AU2017238051B9 (en) | 2022-11-03 |
| CN109310656A (zh) | 2019-02-05 |
| MX382608B (es) | 2025-03-13 |
| KR20180120756A (ko) | 2018-11-06 |
| AU2017238051B2 (en) | 2022-10-06 |
| JP2019509309A (ja) | 2019-04-04 |
| EP3432871A4 (en) | 2019-10-30 |
| CA3017374A1 (en) | 2017-09-28 |
| ES2970294T3 (es) | 2024-05-27 |
| WO2017165409A1 (en) | 2017-09-28 |
| AU2017238051A1 (en) | 2018-10-04 |
| JP2022081640A (ja) | 2022-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12017500070A1 (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
| BR112016005816A2 (pt) | Combinação de anticorpos anti-lag-3 e anticorpos anti-pd-1 para tratar tumores | |
| BR112018008882A2 (pt) | método para tratar um distúrbio proliferativo e produto farmacêutico | |
| CL2015000699A1 (es) | Métodos para tratamiento de cáncer. | |
| MX370506B (es) | Método para tratar trastorno de estrés post-traumático. | |
| PH12015502075A1 (en) | Treatment of cataplexy | |
| ZA202005388B (en) | Methods of treating ulcerative colitis | |
| BR112015023020A2 (pt) | combinação de inibidor de egfr t790m e inibidor de egfr para o tratamento de câncer pulmonar de células não-pequenas | |
| BR112015029386A2 (pt) | uso de eribulina e lenvatinibe como terapia de combinação para tratamento de câncer | |
| BR112018000776A2 (pt) | métodos para tratamento de câncer usando apilimod | |
| CO2019000753A2 (es) | Métodos para tratar el cáncer de próstata | |
| BR112017021312A2 (pt) | tratamento de câncer de pulmão com inibidores de glutaminase | |
| BR112019005040A2 (pt) | aplicação de pridopidina para tratamento de síndrome de rett | |
| MX374749B (es) | Terapia de combinacion que comprende un inhibidor de tor cinasa y un analogo de citidina para tratar cancer. | |
| BR112019001039A2 (pt) | composição para uso no tratamento de transtorno depressivo maior | |
| MX2016015378A (es) | Uso de eribulina en el tratamiento de cancer. | |
| BR112016027043A8 (pt) | combinação, composição farmacêutica compreendendo glucocorticoide e edo-s101, kit e uso no tratamento de câncer | |
| BR112019005539A2 (pt) | métodos de tratamento de lesão renal aguda | |
| BR112015022513A2 (pt) | produto e método para tratamento de diarreia | |
| BR112019008241A2 (pt) | tratamento do prurigo nodular | |
| FI20115165A0 (fi) | Terapeuttisia ja diagnostisia menetelmiä | |
| MX382044B (es) | Oxabicicloheptanos y oxabicicloheptenos para el tratamiento de trastornos depresivos y de estrés. | |
| BR112018013847A2 (pt) | métodos para administrar a angiotensina ii | |
| MX2018011379A (es) | Tratamiento del prurito uremico. | |
| BR112017025264A2 (pt) | tratamento de prurido |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B07D | Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette] |
Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS. |
|
| B07E | Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette] | ||
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B350 | Update of information on the portal [chapter 15.35 patent gazette] | ||
| B07A | Application suspended after technical examination (opinion) [chapter 7.1 patent gazette] | ||
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 7A ANUIDADE. |
|
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2767 DE 16-01-2024 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013. |